Cytoki Pharma ApS: Financial statements 2025
CVR: 40594132
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Cytoki Pharma ApS (CVR 40594132) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -42,198,706 and a net result of DKK -43,800,007 compared with DKK -39,261,697 the year before. Equity in the 2025 report amounted to DKK 13,473,548. The solvency ratio was 75%. The company had 4 employees in the financial year.
- Gross Profit
- DKK -42,198,706
- Profit/Loss
- DKK -43,800,007
- Equity
- DKK 13,473,548
- Total Assets
- DKK 17,962,975
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -42.2 mio. | -43.8 mio. | 13.5 mio. | 4 |
| 2024 | - | -39.1 mio. | -39.3 mio. | 57.3 mio. | 4 |
| 2023 | - | -61.5 mio. | -64.5 mio. | 66.7 mio. | 5 |
| 2022 | - | -98.8 mio. | -98.4 mio. | 51.2 mio. | 4 |
| 2021 | - | -32 mio. | -29.8 mio. | 106.8 mio. | 3 |
Official annual report
How creditworthy is Cytoki Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Cytoki Pharma ApS has published its annual report for 2024. Gross profit came to DKK -39,132,575, and the net result was DKK -39,261,697.
About Cytoki Pharma ApS
Cytoki Pharma ApS is a Danish company of the type Anpartsselskab based in Søborg, founded in 2019. The company is in liquidation. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CytoKi Pharma ApS. The management consists of Anders Hagstrøm. The company's owners include LUNDBECKFOND INVEST A/S, 15-Bio ApS and YSIOS Biofund III, F.C.R.E. The company has 3 employees (2026). In 2025, the company reported a gross profit of DKK -42,198,706 and a net result of DKK -43,800,007 compared with DKK -39,261,697 the year before. Equity in the 2025 report amounted to DKK 13,473,548.